XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
  Breast
  Skin
  Blood
  Prostate
  Liver
  Colon
  Thyroid
  Endometrial
  Brain
  Therapy
  Risk Factors
  Esophageal
  Bladder
  Lung
  Rectal Cancer
  Pancreatic Cancer
  Bone Cancer
  Cervical Cancer
  Testicular Cancer
  Gastric Cancer
  Ovarian Cancer
  Nerve Tissue
  Renal Cell Carcinoma
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
Search

Last Updated: Nov 17th, 2006 - 22:35:04

Endometrial Channel
subscribe to Endometrial newsletter

Latest Research : Cancer : Endometrial

   DISCUSS   |   EMAIL   |   PRINT
Raloxifene May Protect Against Endometrial Cancer
May 17, 2005, 01:54, Reviewed by: Dr.

In a case-control study, researchers compared raloxifene and tamoxifen use between 547 women with endometrial cancer in the Philadelphia area and 1,412 women without cancer who served as controls.

 
A new analysis of patients taking raloxifene and tamoxifen shows that raloxifene may reduce the risk of endometrial cancer (cancer of the uterine lining), and confirms previous studies showing that tamoxifen increases the risk for the disease.

Tamoxifen has been shown to reduce the risk of breast cancer recurrence among women whose cancer is sensitive to estrogen ("hormone receptor positive"), and to reduce the risk of developing breast cancer among women at high risk for the disease. However, this study and others have found that tamoxifen also increases the risk of endometrial cancer. Raloxifene, which belongs to the same class of drugs as tamoxifen called selective estrogen receptor modulators (SERMs) is used to treat osteoporosis and may also reduce the risk of breast cancer. Unlike tamoxifen, however, raloxifene does not stimulate estrogen receptors in the uterine lining.

In a case-control study, researchers compared raloxifene and tamoxifen use between 547 women with endometrial cancer in the Philadelphia area and 1,412 women without cancer who served as controls. Patients were participants in the Women's Insights and Shared Experiences (WISE) study, a project at the University of Pennsylvania School of Medicine that is investigating hormone-related cancers in women. The control group was recruited by random-digit telephone dialing in the Philadelphia area.

Compared to non-users, the risk of endometrial cancer among women taking tamoxifen was 50% higher, while raloxifene users experienced a 50% lower risk. This benefit existed even among women who used raloxifene for less than three years.

"Endometrial cancer is the most common gynecologic cancer, so it's important to start thinking about strategies to reduce risk," said Angela DeMichele, MD, MSCE, Assistant Professor of Medicine at the Abramson Cancer Center and the Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, and the study's lead investigator. "If raloxifene proves effective at preventing both breast cancer and endometrial cancer, that information could weigh heavily on a woman's decision about which drug to choose."

Another study currently underway called the STAR trial (Study of Tamoxifen and Raloxifene) is comparing raloxifene and tamoxifen for reducing the risk of ever developing breast cancer. Data won't be reported until 2006, but may also reveal important findings regarding endometrial cancer risk.
 

- American Society of Clinical Oncology Annual Meeting
 

www.asco.org

 
Subscribe to Endometrial Newsletter
E-mail Address:

 

Lead Author:
Angela DeMichele, MD, MSCE
University of Pennsylvania
Philadelphia, PA


Related Endometrial News

Adjuvant radiotherapy improves survival in Stage I Endometrial Cancer
Raloxifene May Protect Against Endometrial Cancer
Cancer Risk Highest in Combined HRT
Broadening treatment to battle recurrence of endometrial cancer


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us